Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease

被引：2
作者：
Musto J. [1 ,2 ]
Spengler E.K. [1 ,2 ]
German M.N. [1 ,2 ]
机构：
[1] Division of Gastroenterology and Hepatology, Department of Medicine, 4264 MFCB, 1685 Highland Avenue, Madison, 53705, WI
[2] School of Medicine and Public Health, University of Wisconsin, 4000 MFCB, 1685 Highland Avenue, Madison, 53705, WI
来源：
Current Hepatology Reports | 2021年 / 20卷 / 4期
关键词：
Estrogen; Gender; Metabolic syndrome; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Sex differences;
D O I：
10.1007/s11901-021-00568-8
中图分类号：
学科分类号：
摘要：
Purpose of Review: This review focuses on how sex differences play a role in the development and progression of NAFLD, describe inconsistencies in current findings, and propose goals for future studies. Recent Findings: NAFLD prevalence and severity is higher in men than in premenopausal women. After menopause, prevalence of NAFLD increases, suggesting a protective effect of estrogen. Androgen excess may also increase the risk of steatosis in women. Furthermore, there is a strong interplay between hormonal changes and development of visceral adiposity and metabolic syndrome, both closely related to NAFLD progression. Summary: Despite advancements in research, our understanding of sexual dimorphism in NAFLD remains incomplete. While results are varied, it is apparent that sex differences with regard to endogenous hormones, reproductive stage, metabolic risk factors, and body fat distribution all play a significant role in the development of NAFLD. Future studies should aim to develop sex-specific therapies to mitigate the rising prevalence of NAFLD. © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021.
引用
收藏
页码：97 / 107
页数：10
相关论文
共 97 条
  • [1] Noureddin M., Vipani A., Bresee C., Todo T., Kim I.K., Alkhouri N., Et al., NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances, Am J Gastroenterol, 113, pp. 1649-1659, (2018)
  • [2] Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., Younossi I., Et al., Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 19, (2021)
  • [3] Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Et al., The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, pp. 328-357, (2018)
  • [4] MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 158, (2020)
  • [5] Ballestri S., Nascimbeni F., Baldelli E., Marrazzo A., Romagnoli D., Lonardo A., NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk, Adv Ther, 34, pp. 1291-1326, (2017)
  • [6] Araujo A.R., Rosso N., Bedogni G., Tiribelli C., Bellentani S., Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future, Liver Int, 38, pp. 47-51, (2018)
  • [7] Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., Et al., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, pp. 11-20, (2018)
  • [8] McGlynn K.A., Petrick J.L., El-Serag H.B., Epidemiology of hepatocellular carcinoma, Hepatology, 73, pp. 4-13, (2021)
  • [9] Lonardo A., Suzuki A., Nonalcoholic fatty liver disease: does sex matter?, Hepatobiliary Surg Nutr, 8, pp. 164-166, (2019)
  • [10] Lonardo A., Nascimbeni F., Ballestri S., Fairweather D., Win S.T.A., Sex differences in nonalcoholic fatty liver disease: State of the art and identification of research gaps, Hepatology, 70, pp. 1457-1469, (2019)
12345678910